LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

1996: First European Commission-approved product following European Agency for the Evaluation of Medicinal Products (EMEA, later EMA) recommendation

18/06/2021

Nominated by: Voisin Consulting Life Sciences

Organisation in nomination: European Commission 

1996 saw the first legal/regulatory framework for medicinal products in the European Union.

GONAL-f from Serono Laboratories was the first product recommended for approval via a centralised procedure and published in the EU Journal on 26 January.  The landmark approval demonstrated the EU integrated system for Medicinal Products approval and review, leading to the European Union granting Marketing Authorisation based on the EMEA’s Committee for Medicinal Products for Human Use (CMPH) recommendation.

It was a notable approval as the product is primarily used to treat women with sub-fertility.

Today, this is now the European Medicines Agency (EMA), based in Amsterdam and currently headed by Emer Cooke, provides scientific advice to innovators, expedited pathways to marketing authorisation and ensures high standards for human and veterinary medicines. Seven EMA scientific committees provide scientific expertise for the regulation of medicines by drawing on a network of over 4500 European scientific experts and using resources of over 40 National Competent Authorities (NCAs) of EU Member states.

The EMA oversees products developed in specialised areas of medicine such as Advanced Therapy Medicinal Products (ATMP), rare diseases, herbal medicines and medicines for children.

References:

  • Summary of Community Decisions on marketing authorizations in respect of medicinal products from 15 October 1995 to 15 January 1996
  • EMA public stakeholder meeting on the approval, safety monitoring and
    impact of COVID-19 vaccines in the EU
  • Emer Cook takes office as head of EMA
  • European Medicines Agency official website

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.